IL109639A - High-concentration pharmaceutical preparations and methods for their preparation - Google Patents

High-concentration pharmaceutical preparations and methods for their preparation

Info

Publication number
IL109639A
IL109639A IL109639A IL10963994A IL109639A IL 109639 A IL109639 A IL 109639A IL 109639 A IL109639 A IL 109639A IL 10963994 A IL10963994 A IL 10963994A IL 109639 A IL109639 A IL 109639A
Authority
IL
Israel
Prior art keywords
mycophenolate mofetil
active agent
temperature
pharmaceutical formulation
liquefied
Prior art date
Application number
IL109639A
Other languages
English (en)
Hebrew (he)
Other versions
IL109639A0 (en
Inventor
Glenn Jay Samuels
Jung-Chung Lee
Charles Lee
Stephen Berry
Paul Joseph Jarosz
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of IL109639A0 publication Critical patent/IL109639A0/xx
Publication of IL109639A publication Critical patent/IL109639A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL109639A 1993-05-13 1994-05-12 High-concentration pharmaceutical preparations and methods for their preparation IL109639A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/061,656 US5455045A (en) 1993-05-13 1993-05-13 High dose formulations

Publications (2)

Publication Number Publication Date
IL109639A0 IL109639A0 (en) 1994-08-26
IL109639A true IL109639A (en) 1998-02-08

Family

ID=22037233

Family Applications (1)

Application Number Title Priority Date Filing Date
IL109639A IL109639A (en) 1993-05-13 1994-05-12 High-concentration pharmaceutical preparations and methods for their preparation

Country Status (23)

Country Link
US (3) US5455045A (pl)
EP (1) EP0697866B1 (pl)
JP (1) JP3584037B2 (pl)
KR (1) KR100296214B1 (pl)
CN (1) CN1045884C (pl)
AT (1) ATE187067T1 (pl)
AU (1) AU674960B2 (pl)
BR (2) BR9406604A (pl)
CZ (1) CZ285297B6 (pl)
DE (1) DE69421918T2 (pl)
DK (1) DK0697866T3 (pl)
ES (1) ES2138661T3 (pl)
FI (1) FI114286B (pl)
GR (1) GR3032021T3 (pl)
HU (2) HU226470B1 (pl)
IL (1) IL109639A (pl)
NO (1) NO308828B1 (pl)
NZ (1) NZ266683A (pl)
PL (1) PL175583B1 (pl)
PT (1) PT697866E (pl)
RU (1) RU2135182C1 (pl)
TW (1) TW434010B (pl)
WO (1) WO1994026266A1 (pl)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002520A1 (en) * 1989-08-17 1991-03-07 Cortecs Limited Pharmaceutical formulations
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
MX9707585A (es) * 1995-04-03 1997-12-31 Abbott Lab Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada.
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
CN1227004C (zh) 2000-02-18 2005-11-16 Cv治疗公司 治疗充血性心力衰竭的部分脂肪酸氧化抑制剂
WO2001062711A2 (en) 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
WO2001062749A1 (en) 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted piperazine compounds
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
JP2006510670A (ja) * 2002-12-05 2006-03-30 シーブイ・セラピューティクス・インコーポレイテッド 置換ヘテロ環化合物
WO2004063180A1 (en) * 2003-01-03 2004-07-29 Cv Therapeutics, Inc. Substituted heterocyclic compounds
AU2004209522A1 (en) * 2003-01-17 2004-08-19 Gilead Palo Alto, Inc. Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
CA2530376A1 (en) * 2003-06-23 2005-01-06 Cv Therapeutics, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
EP1723129A1 (en) 2003-12-18 2006-11-22 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
WO2005105768A2 (en) * 2004-04-26 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolic acid and ester derivatives thereof
US7358247B2 (en) * 2004-04-27 2008-04-15 TEVA Gyógyszergyár Zártköruen Muködö Részvénytársaság Mycophenolate mofetil impurity
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US7439373B2 (en) * 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
EP1789407A2 (en) * 2004-09-08 2007-05-30 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
KR20070093988A (ko) * 2005-01-06 2007-09-19 씨브이 쎄러퓨틱스, 인코포레이티드 라놀라진 함유 서방성 약제학적 제형물
CN100393312C (zh) * 2005-04-18 2008-06-11 吴建梅 霉酚酸或其类似物的软胶囊及其制备方法
US20080280977A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
CA2656903A1 (en) * 2006-07-06 2008-01-10 Ares Trading S.A. An oral pharmaceutical composition of anilinopyrimidine, preparation and use thereof
WO2008022284A2 (en) * 2006-08-16 2008-02-21 Aspreva Pharmaceuticals Ltd. Compositions and methods for treating vascular, autoimmune, and inflammatory diseases
EP2117550A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
CA2678272A1 (en) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
US20090076000A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched mycophenolate mofetil
AR068745A1 (es) * 2007-10-08 2009-12-02 Panacea Biotec Ltd Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos
BRPI0908428A2 (pt) * 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
WO2010004435A2 (en) * 2008-07-09 2010-01-14 Aspreva International Ltd. Formulations for treating eye disorders
US9012192B2 (en) * 2008-08-26 2015-04-21 Intelligentnano Inc. Ultrasound enhanced growth of microorganisms
EP2326717A4 (en) 2008-08-26 2011-12-28 Intelligentnano Inc ON THE BASIS OF ULTRASONIC REINFORCED GROWTH OF MICROORGANISMS
US8962290B2 (en) 2008-08-26 2015-02-24 Intelligentnano Inc. Enhanced animal cell growth using ultrasound
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
AU2010249615B2 (en) * 2009-05-19 2013-07-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
WO2010137040A2 (en) 2009-05-28 2010-12-02 Lupin Limited Novel pharmaceutical compositions of ranolazine
WO2011036677A2 (en) 2009-09-25 2011-03-31 Lupin Limited Sustained release composition of ranolazine
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
WO2022063266A1 (zh) 2020-09-27 2022-03-31 中国石油化工股份有限公司 歧化与烷基转移催化剂及其制备和应用
CN114456835B (zh) 2020-10-22 2023-06-06 中国石油化工股份有限公司 一种汽油组分的处理系统和处理方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3374146A (en) * 1966-04-18 1968-03-19 American Cyanamid Co Sustained release encapsulation
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
JPS5542995B2 (pl) * 1972-02-24 1980-11-04
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US3903071A (en) * 1973-05-22 1975-09-02 Lilly Co Eli Mycophenolic acid derivatives
US4002718A (en) * 1974-10-16 1977-01-11 Arnar-Stone Laboratories, Inc. Gelatin-encapsulated digoxin solutions and method of preparing the same
US4145918A (en) * 1976-09-07 1979-03-27 Akzona Incorporated Freeze-thaw indicator
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
CA1125698A (en) * 1978-03-09 1982-06-15 Masaru Yoshida Process for preparing a polymer composition
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
DK164642C (da) * 1984-08-30 1992-12-14 Merrell Dow Pharma Farmaceutisk middel indeholdende terfenadin i form af en varmsmelte paafyldt paa kapsler
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
US4820523A (en) * 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
DE3613799C1 (de) * 1986-04-24 1987-09-03 Nattermann A & Cie Verwendung von Glycofurol zum Verfluessigen von Arzneimittelzubereitungen fuer das Abfuellen in Weichgelatinekapseln
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US4727069A (en) * 1987-01-30 1988-02-23 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
US5175000A (en) * 1987-06-30 1992-12-29 Vipont Pharmaceutical, Inc. Free amine benzophenanthridine alkaloid compositions
US4936074A (en) * 1988-11-17 1990-06-26 D. M. Graham Laboratories, Inc. Process for preparing solid encapsulated medicament
EP0465565B1 (en) * 1989-03-31 1996-05-15 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
WO1991006281A1 (en) * 1989-10-26 1991-05-16 Nippon Shinyaku Co., Ltd. Gastric preparation
FR2657257B1 (fr) * 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
KR100215167B1 (ko) * 1990-08-10 1999-08-16 위샤르트 아이 시 면역 억제 조성물
US5247083A (en) * 1992-07-10 1993-09-21 Syntex (U.S.A.) Inc. Direct esterification of mycophenolic acid
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US5380879A (en) * 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
US5467037A (en) * 1994-11-21 1995-11-14 International Business Machines Corporation Reset generation circuit to reset self resetting CMOS circuits

Also Published As

Publication number Publication date
PT697866E (pt) 2000-04-28
KR960702304A (ko) 1996-04-27
FI114286B (fi) 2004-09-30
ES2138661T3 (es) 2000-01-16
ATE187067T1 (de) 1999-12-15
NO308828B1 (no) 2000-11-06
CZ285297B6 (cs) 1999-06-16
CN1122571A (zh) 1996-05-15
PL311654A1 (en) 1996-03-04
DE69421918D1 (de) 2000-01-05
HU9503224D0 (en) 1996-01-29
EP0697866B1 (en) 1999-12-01
AU6830194A (en) 1994-12-12
NZ266683A (en) 1996-08-27
HU211270A9 (en) 1995-11-28
FI955439A (fi) 1995-11-10
AU674960B2 (en) 1997-01-16
GR3032021T3 (en) 2000-03-31
CN1045884C (zh) 1999-10-27
BR1100723A (pt) 2000-04-18
US5472707A (en) 1995-12-05
WO1994026266A1 (en) 1994-11-24
NO954546D0 (no) 1995-11-10
KR100296214B1 (ko) 2001-10-24
BR9406604A (pt) 1996-01-02
US5455045A (en) 1995-10-03
HUT72978A (en) 1996-06-28
RU2135182C1 (ru) 1999-08-27
EP0697866A1 (en) 1996-02-28
NO954546L (no) 1995-11-10
TW434010B (en) 2001-05-16
CZ295495A3 (en) 1996-02-14
HU226470B1 (en) 2008-12-29
DE69421918T2 (de) 2000-03-30
US5554384A (en) 1996-09-10
JPH08510254A (ja) 1996-10-29
PL175583B1 (pl) 1999-01-29
FI955439A0 (fi) 1995-11-10
IL109639A0 (en) 1994-08-26
DK0697866T3 (da) 2000-04-17
JP3584037B2 (ja) 2004-11-04

Similar Documents

Publication Publication Date Title
EP0697866B1 (en) High dose formulations
EP0097523B1 (en) Extended action controlled release compositions
DE69405752T2 (de) Filmbeschichtete tablette von astemizol und pseudoephedrin mit verlängerter freigabe
EP0801562A1 (en) Pharmaceutical composition containing fenofibrate and polyglycolized glycerides
WO2002011701A1 (en) A controlled release pharmaceutical composition
US3459850A (en) Sustained-release tablets,a process and a composition for their preparation
DK159590B (da) Fremgangsmaade til forhindring af nedbrydning af thieno-pyridinderivater
US8901128B2 (en) Pharmaceutical compositions of ranolazine
EP0299668B1 (en) Pharmaceutical composition containing ibuprofen
CA2162670C (en) High dose formulations of mycophenolate mofetil, mycophenolic acid and ranolazine
CN112741827A (zh) 氨己烯酸固体制剂及其制备方法
US3140229A (en) Laxative compositions containing (4, 4'-dihydroxy-2''-amino)-triphenylmethane and method of using same
AU2004285316A1 (en) Pharmaceutical compositions based on idazoxan salt or one of the polymorphs thereof
US4105796A (en) Pharmaceutical compositions containing racemic or optically active 1-(2,6-dimethyl-phenoxy)-2-methylamino-propane and method of use
CN107007559B (zh) 一种稳定的口服药物组合物及其制备方法
CN115429797A (zh) 一种含氧氯吡格雷或其盐的组合物及其制备
SK284769B6 (sk) Farmaceutické formulácie obsahujúce pentaerytrityltetranitrát alebo jeho metabolity a spôsob jeho prípravy
MXPA00011159A (en) 8-chloro-6,11-dihydro-11- (4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine oral compositions

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired